ストックスクリーナーアプリを入手
0.35
47.72%
-0.3195
アフターアワーズ：
.35
前日終値:
$0.6695
開ける：
$0.2
24時間の取引高:
148.80K
Relative Volume:
0.41
時価総額：
$434.88K
収益：
-
当期純損益:
$-13.24M
株価収益率:
-0.0396
EPS:
-8.83
ネットキャッシュフロー:
$-16.85M
1週間 パフォーマンス:
-73.88%
1か月 パフォーマンス:
-92.63%
6か月 パフォーマンス:
-97.82%
1年 パフォーマンス:
-99.66%
1日の値動き範囲:
$0.13
$0.45
1週間の範囲:
$0.13
$1.7778
52週間の値動き範囲:
$0.13
$101.32
Virpax Pharmaceuticals Inc Stock (VRPX) Company Profile
名前
Virpax Pharmaceuticals Inc
セクター
電話
610-727-4597
住所
1055 WESTLAKES DRIVE, SUITE 300, BERWYN
VRPX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VRPX
Virpax Pharmaceuticals Inc
|
0.35 | 434.88K | 0 | -13.24M | -16.85M | -8.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Virpax Pharmaceuticals Inc (VRPX) 最新ニュース
Virpax Pharmaceuticals to be delisted from Nasdaq By Investing.com - Investing.com South Africa
Virpax Pharmaceuticals stock plummets on Nasdaq delisting news - Investing.com
Virpax Pharmaceuticals to be delisted from Nasdaq - Investing.com
Promising Nanotechnology Stocks To ResearchMarch 29th - MarketBeat
Promising Nanotechnology Stocks To Watch NowMarch 22nd - MarketBeat
Virpax Pharmaceuticals enacts 1-for-25 reverse stock split By Investing.com - Investing.com Australia
Virpax Pharmaceuticals enacts 1-for-25 reverse stock split - Investing.com India
VRPX stock plunges to 52-week low of $0.12 amid market challenges - Investing.com Australia
Virpax Pharmaceuticals Announces the Formation of Novvae™ Pharmaceuticals - Business Wire
Virpax Pharmaceuticals announces 1-for-25 reverse stock split By Investing.com - Investing.com South Africa
VRPX stock plunges to 52-week low of $0.12 amid market challenges By Investing.com - Investing.com South Africa
Virpax Pharmaceuticals announces 1-for-25 reverse stock split - Investing.com India
Virpax Pharmaceuticals Announces Reverse Stock Split - Business Wire
Virpax Reports Positive Results From Dose Range Finding Study of Pain Relief Treatment in Beagle Dogs - MarketScreener
Why StoneCo Shares Are Trading Higher By 8%; Here Are 20 Stocks Moving Premarket - Benzinga
Virpax receives positive Probudur(TM) results for dose range study -March 18, 2025 at 05:34 pm EDT - Marketscreener.com
Virpax reports positive results in Probudur dog study By Investing.com - Investing.com Australia
Virpax reports positive results in Probudur dog study - Investing.com
Breakthrough: Virpax's 5-Day Pain Drug Passes Critical Safety Test - StockTitan
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Virpax Pharmaceuticals to Present NES100 Toxicity Study at Major Toxicology Conference - MSN
Virpax Pharmaceuticals Explores Intranasal mRNA Vaccine Delivery Using MET - MSN
Virpax Pharmaceuticals stock hits 52-week low at $0.18 By Investing.com - Investing.com Australia
Virpax Pharmaceuticals stock hits 52-week low at $0.18 - Investing.com
Nanotechnology Stocks To Follow Now – March 7th - Defense World
Virpax Looking To Use Met To Develop Intranasal Covid Vaccine -March 07, 2025 at 08:36 am EST - Marketscreener.com
Virpax Looking to Use MET to Develop Intranasal COVID Vaccine - The Bakersfield Californian
Could This Needle-Free COVID Vaccine Technology Transform Vaccine Delivery? - StockTitan
Virpax Pharmaceuticals Applauds Successful Trial of Molecular Envelope Technology - MSN
Can Virpax's Nasal Pain Treatment Solve the Opioid Addiction Problem? - StockTitan
Stock Market Update – Virpax Pharmaceuticals Stock Price Prediction 2025 - ldccbank
Short Interest in Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Expands By 148.7% - Defense World
Virpax Pharmaceuticals Stock Price, Quotes and Forecasts | NASDAQ:VRPX - Benzinga
Virpax lauds Nanomerics’ MET study with no severe side effects By Investing.com - Investing.com Australia
VRPX Soars On MET Results, COLL Projects 16%-19% Revenue Growth In 2025, RPID Gains Momentum - RTTNews
Stocks Under $1: PMAX PRSO ARBB KAVL to Watch in March 2025 – More Stocks Inside - Financial Content
Virpax Pharmaceuticals reports Molecular Envelope Technology human study data - TipRanks
Virpax lauds Nanomerics' MET study with no severe side effects - Investing.com
Virpax lauds Nanomerics’ MET study with no severe side effects - Investing.com India
Can Virpax's Breakthrough Drug Delivery Tech Transform Pain Management Without Opioid Risks? - StockTitan
Virpax(R) Pharmaceuticals to Present at ThinkEquity Conference - ACCESS Newswire
Virpax Pharmaceuticals Inc (VRPX) 財務データ
収益
当期純利益
現金流量
EPS
3.01%
大文字化:
|
ボリューム (24 時間):